Meeting
2023 ASCO Quality Care Symposium
Economic burden and healthcare resource utilization (HRU) associated with cystectomy (CYS) in US patients with muscle invasive bladder cancer (MIBC).
Authors
Qian Shi
Janssen Scientific Affairs, LLC, Horsham, PA
Qian Shi, Bruno Emond, Laura Morrison, Anabelle Tardif-Samson, Dominic Pilon, Patrick Lefebvre, Lorie Ellis, Andrea Ireland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Cost and Cost-Effectiveness of Care
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 17)
DOI
10.1200/OP.2023.19.11_suppl.17
Abstract #
17
Poster Bd #
A12
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Bladder-preserving therapy using a real-time tumor-tracking radiotherapy system for muscle-invasive bladder cancer.
First Author: Haruka Miyata
Poster
2016 ASCO Annual Meeting
Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC).
First Author: Tracy Lynn Rose
Poster
2016 Genitourinary Cancers Symposium
Are we systemically under treating cisplatin-eligible patients with muscle invasive bladder cancer (MIBC) who are undergoing bladder preservation by chemoradiotherapy?
First Author: Srikala S. Sridhar
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy and safety of the combination of cisplatin plus nab-paclitaxel and nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive bladder cancer (CNN-BC trial).
First Author: Chiara Ciccarese